Zobrazeno 1 - 10
of 14
pro vyhledávání: '"M. A. Ströhlein"'
Publikováno v:
best practice onkologie. 6:16-23
Autor:
M. A. Ströhlein
Publikováno v:
Zentralblatt für Chirurgie. 135:508-515
Background: Pleural effusions and ascites are associated with distressing symptoms like dys- pnoea, intestinal obstruction, vomiting, nausea and pain. In patients with underlying malignancy, the prognosis is limited to few months. After unsuccessful
Autor:
M. A. Ströhlein, M. M. Heiss
Publikováno v:
Viszeralchirurgie. 41:231-236
Publikováno v:
Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 86(4)
Appendicectomy (AE), the most frequent emergency surgical procedure, can be performed as a transvaginal hybrid natural orifice translumenal endoscopic surgery (NOTES) technique (TVAE). The question of feasibility also arises in cases of advanced infl
Publikováno v:
Zentralblatt für Chirurgie. 136
Autor:
M A, Ströhlein
Publikováno v:
Zentralblatt fur Chirurgie. 135(6)
Pleural effusions and ascites are associated with distressing symptoms like dyspnoea, intestinal obstruction, vomiting, nausea and pain. In patients with underlying malignancy, the prognosis is limited to few months. After unsuccessful medical treatm
Publikováno v:
Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 81(11)
The need for red blood cell units in cancer surgery is increasing. The role of the better immunological options, such as preoperative blood donation or intraoperative autologous blood salvage is not known. The aim of this survey was to clarify the tr
Autor:
M A, Ströhlein, M M, Heiss
Publikováno v:
Cancer treatment and research. 134
Intraperitoneal immunotherapy actually is a promising concept for treatment of peritoneal carcinomatosis for several reasons: The use of specifically engineered therapy in terms of antibodies or stimulated T lymphocytes against epithelial tumour anti
Publikováno v:
Transplantation Journal. 94:1104
Autor:
Simon L. Parsons, M. A. Ströhlein, D. Seimetz, Dirk Arnold, Horst Lindhofer, M. Hennig, Carsten Bokemeyer, M. G. Ott, Markus M. Heiss, Elisabeth Schulze
Publikováno v:
Journal of Clinical Oncology. 29:2512-2512
2512 Background: Catumaxomab (anti-EpCAM x anti-CD3) is approved in the EU for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas. Here we report the foll...